UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 2.168

Sortiert nach

Analysis of the concordance in the EGFR pathway status between primary tumors and related metastases of colorectal cancer patients:implications for cancer therapy

Current cancer drug targets, 2012-02, Vol.12 (2), p.124

2012

Volltextzugriff (PDF)

Association of creatine kinase and skin toxicity in phase I trials of anticancer agents

British journal of cancer, 2012-11, Vol.107 (11), p.1797-1800

2012

Volltextzugriff (PDF)

Prognostic value of carcinoembryonic antigen level in rectal cancer treated with neoadjuvant chemoradiotherapy

International journal of colorectal disease, 2009-07, Vol.24 (7), p.741-748

2009

Volltextzugriff (PDF)

Color Space Mathematical Modeling Using Microsoft Excel

Journal of chemical education, 2018-10, Vol.95 (10), p.1885-1889

2018

Volltextzugriff (PDF)

Creatinine Clearance Is Associated with Toxicity from Molecularly Targeted Agents in Phase I Trials

Oncology, 2012-08, Vol.83 (4), p.177-182

2012

Volltextzugriff (PDF)

Treatment of esophageal perforation: A review of our experience at a tertiary referral hospital spanning the past 19 years

Revista de Gastroenterología de México (English Edition), 2022-10, Vol.87 (4), p.405-410

2022

Volltextzugriff (PDF)

Study of a laboratory-scaled new method for the accelerated continuous ageing of wine spirits by applying ultrasound energy

Ultrasonics sonochemistry, 2017-05, Vol.36, p.226-235

2017

Volltextzugriff (PDF)

Immunohistochemical analysis of tumour regression grade for rectal cancer after neoadjuvant chemoradiotherapy

Colorectal disease, 2011-09, Vol.13 (9), p.989-998

2011

Volltextzugriff (PDF)

40P Bioinformatic evaluation of the transcriptomic and immunologic profile of prostate tumors with high expression of kallikrein-2

Annals of oncology, 2023-10, Vol.34, p.S199-S199

2023

Volltextzugriff (PDF)

85P In silico evaluation of the transcriptomic and immunologic profile of lung adenocarcinomas with deletions or disruptive mutations of SMARCA4

Annals of oncology, 2023-10, Vol.34, p.S212-S212

2023

Volltextzugriff (PDF)

362P Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in head and neck squamous cell cancer (HNSCC)

Annals of oncology, 2023-11, Vol.34, p.S1610-S1611

2023

Volltextzugriff (PDF)

673P A phase I dose-escalation and expansion study evaluating the safety and efficacy of the MDM2–p53 antagonist brigimadlin (BI 907828) in patients (pts) with solid tumours

Annals of oncology, 2023-10, Vol.34, p.S472-S473

2023

Volltextzugriff (PDF)

First-line ADP-A2M4CD8 T-cell Receptor T-cell Therapy plus Pembrolizumab in Head and Neck Cancers: An Additional Cohort of the Phase 1 SURPASS Trial

International journal of radiation oncology, biology, physics, 2024-04, Vol.118 (5), p.e84-e85

2024

Volltextzugriff (PDF)

176P Liver pharmacodynamics in an open-label phase Ib/IIa study of fostroxacitabine bralpamide (fostrox, MIV-818) in combination with lenvatinib in 2L/3L hepatocellular carcinoma

Annals of oncology, 2024-06, Vol.35, p.S80-S80

2024

Volltextzugriff (PDF)

1075TiP A phase I/Ib open-label, first-in-human, single agent, dose escalation and expansion study of a HER2-targeted T cell engager (SAR443216) in patients with relapsed/refractory HER2-expressing solid tumors

Annals of oncology, 2023-10, Vol.34, p.S647-S647

2023

Volltextzugriff (PDF)

Discriminant ability of phenolic compounds and short chain organic acids profiles in the determination of quality parameters of Brandy de Jerez

Food chemistry, 2019-07, Vol.286, p.275-281

2019

Volltextzugriff (PDF)

392P Updated data of biodistribution and activity of oncolytic virus TG6002 after intravenous administration in patients with advanced gastrointestinal carcinomas

Annals of oncology, 2022-09, Vol.33, p.S716

2022

Volltextzugriff (PDF)

488P Phase I trial of PF-06821497, a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in follicular lymphoma (FL), small cell lung cancer (SCLC) and castration-resistant prostate cancer (CRPC)

Annals of oncology, 2022-09, Vol.33, p.S763-S764

2022

Volltextzugriff (PDF)

486P Bioavailability and activity of oncolytic virus TG6002 after intravenous administration in patients with advanced gastrointestinal carcinomas

Annals of oncology, 2021-09, Vol.32, p.S572-S573

2021

Volltextzugriff (PDF)

MCLA-129, a human anti-EGFR and anti-c-MET bispecific antibody, in patients with advanced NSCLC and other solid tumors: an ongoing phase 1/2 study

European journal of cancer (1990), 2022-10, Vol.174, p.S122-S122

2022

Volltextzugriff (PDF)

500O Trotabresib (CC-90010) combined with concomitant temozolomide (TMZ) plus radiotherapy (RT) and adjuvant TMZ in patients (pts) with newly diagnosed primary glioblastoma (ndGBM): Updated results from a phase Ib/II study

Annals of oncology, 2023-10, Vol.34, p.S392-S392

2023

Volltextzugriff (PDF)

745P Clinical activity, safety, and PK/PD from the first in human study (NP41300) of RO7247669, a PD1-LAG3 bispecific antibody

Annals of oncology, 2022-09, Vol.33, p.S884-S885

2022

Volltextzugriff (PDF)

780TiP A phase I dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of CLN-619 (anti-MICA/MICB Antibody) alone and in combination with pembrolizumab in patients with advanced malignancies

Annals of oncology, 2022-09, Vol.33, p.S897-S898

2022

Volltextzugriff (PDF)

740P Anti-cytotoxic T-lymphocyte antigen-4 (CTLA 4) probody BMS-986249 ± nivolumab (NIVO) in patients (pts) with advanced cancers: Updated phase I results

Annals of oncology, 2022-09, Vol.33, p.S882

2022

Volltextzugriff (PDF)

516MO Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, combined with osimertinib, as first-line therapy or after progression on osimertinib in non-small cell lung cancer (NSCLC)

Annals of oncology, 2023-11, Vol.34, p.S1671

2023

Volltextzugriff (PDF)

1 – 25 von 2.168

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.897)
Mit Volltextzugriff
(1.878)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

4 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Analysis of the concordance in the EGFR pathway status between primary tumors and related metastases of colorectal cancer patients:implications for cancer therapy

Association of creatine kinase and skin toxicity in phase I trials of anticancer agents

Prognostic value of carcinoembryonic antigen level in rectal cancer treated with neoadjuvant chemoradiotherapy

Color Space Mathematical Modeling Using Microsoft Excel

Creatinine Clearance Is Associated with Toxicity from Molecularly Targeted Agents in Phase I Trials

Treatment of esophageal perforation: A review of our experience at a tertiary referral hospital spanning the past 19 years

Study of a laboratory-scaled new method for the accelerated continuous ageing of wine spirits by applying ultrasound energy

Immunohistochemical analysis of tumour regression grade for rectal cancer after neoadjuvant chemoradiotherapy

40P Bioinformatic evaluation of the transcriptomic and immunologic profile of prostate tumors with high expression of kallikrein-2

85P In silico evaluation of the transcriptomic and immunologic profile of lung adenocarcinomas with deletions or disruptive mutations of SMARCA4

362P Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in head and neck squamous cell cancer (HNSCC)

673P A phase I dose-escalation and expansion study evaluating the safety and efficacy of the MDM2–p53 antagonist brigimadlin (BI 907828) in patients (pts) with solid tumours

First-line ADP-A2M4CD8 T-cell Receptor T-cell Therapy plus Pembrolizumab in Head and Neck Cancers: An Additional Cohort of the Phase 1 SURPASS Trial

176P Liver pharmacodynamics in an open-label phase Ib/IIa study of fostroxacitabine bralpamide (fostrox, MIV-818) in combination with lenvatinib in 2L/3L hepatocellular carcinoma

1075TiP A phase I/Ib open-label, first-in-human, single agent, dose escalation and expansion study of a HER2-targeted T cell engager (SAR443216) in patients with relapsed/refractory HER2-expressing solid tumors

Discriminant ability of phenolic compounds and short chain organic acids profiles in the determination of quality parameters of Brandy de Jerez

392P Updated data of biodistribution and activity of oncolytic virus TG6002 after intravenous administration in patients with advanced gastrointestinal carcinomas

488P Phase I trial of PF-06821497, a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in follicular lymphoma (FL), small cell lung cancer (SCLC) and castration-resistant prostate cancer (CRPC)

486P Bioavailability and activity of oncolytic virus TG6002 after intravenous administration in patients with advanced gastrointestinal carcinomas

MCLA-129, a human anti-EGFR and anti-c-MET bispecific antibody, in patients with advanced NSCLC and other solid tumors: an ongoing phase 1/2 study

500O Trotabresib (CC-90010) combined with concomitant temozolomide (TMZ) plus radiotherapy (RT) and adjuvant TMZ in patients (pts) with newly diagnosed primary glioblastoma (ndGBM): Updated results from a phase Ib/II study

745P Clinical activity, safety, and PK/PD from the first in human study (NP41300) of RO7247669, a PD1-LAG3 bispecific antibody

780TiP A phase I dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of CLN-619 (anti-MICA/MICB Antibody) alone and in combination with pembrolizumab in patients with advanced malignancies

740P Anti-cytotoxic T-lymphocyte antigen-4 (CTLA 4) probody BMS-986249 ± nivolumab (NIVO) in patients (pts) with advanced cancers: Updated phase I results

516MO Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, combined with osimertinib, as first-line therapy or after progression on osimertinib in non-small cell lung cancer (NSCLC)

Suchergebnisse filtern